Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease

Haruo Nishijima,1,2 Yasuo Miki,3 Shinya Ueno,2 and Masahiko Tomiyama1,2

1Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan
2Department of Neurophysiology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
3Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

Correspondence should be addressed to Haruo Nishijima; hnishijima-tky@umin.ac.jp

Received 28 August 2018; Accepted 21 November 2018; Published 18 December 2018

Academic Editor: Fabrizio Stocchi

Copyright © 2018 Haruo Nishijima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zonisamide is a relatively recent drug for Parkinson’s disease. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide. However, it is still unclear whether the effect of zonisamide is mainly due to dopaminergic modification in the striatum, or if zonisamide works through nondopaminergic pathways. We conducted the present study to determine the mechanism that is mainly responsible for zonisamide’s effects in Parkinson’s disease. We examined the effects of zonisamide on motor symptoms in a hemiparkinsonian rat model when administered singly, coadministered with levodopa, a dopamine precursor, or apomorphine, a D1 and D2 dopamine receptor agonist. We used 6-hydroxydopamine-lesioned hemiparkinsonian rats, which were allocated to one of five groups: 14 rats received levodopa only (6mg/kg), 12 rats received levodopa (6mg/kg) plus zonisamide (50mg/kg), six rats received apomorphine only (0.05mg/kg), six rats received apomorphine (0.05mg/kg) plus zonisamide (50mg/kg), and six rats received zonisamide only (50mg/kg). PG_he drugs were administered once daily for 15 days. We evaluated abnormal involuntary movement every 20 min during a 3 h period following the injection of drugs on treatment Days 1, 8, and 15. Western blot analyses for dopamine decarboxylase and vesicular monoamine transferase-2 were performed using striatal tissues in the lesioned side of rats in the levodopa only group (n = 6) and levodopa plus zonisamide group (n = 4). Levodopa-induced abnormal involuntary movement was significantly enhanced by coadministration of zonisamide. In contrast, zonisamide had no effect on apomorphine-induced abnormal involuntary movement. Zonisamide monotherapy did not induce abnormal involuntary movement. Zonisamide did not affect striatal expression of dopamine decarboxylase or vesicular monoamine transferase-2. In conclusion, zonisamide appears to generate its antiparkinsonian effects by modulating levodopa-dopamine metabolism in the parkinsonian striatum.

1. Introduction

Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor symptoms such as tremor, akinesia, hypokinesia, rigidity, and postural disturbance [1]. The most effective treatment for PD is dopamine replacement therapy using the dopamine precursor, L-3,4-dihydroxypheynalanine (levodopa, L-dopa) [2]. Other drugs are also used to treat PD, including dopamine agonists, catechol-O-methyltransferase inhibitor, monoamine oxidase-B inhibitor, N-methyl-D-aspartate receptor antagonist (amantadine), and adenosine A2A receptor antagonist (istradefylline) [3]. 1,2-Benzisoxazole-3-methaesulfonamid (zonisamide) is an antiparkinsonian drug developed relatively recently. It has been primarily used as an antiepileptic drug and has been reported to be efficacious in the treatment of PD [4]. The beneficial effects of zonisamide in PD were serendipitously found in a patient who had epilepsy and PD [4]. Subsequent clinical research has revealed that a relatively low dose of zonisamide (25–50 mg/day), compared with the dose for epilepsy (200–600 mg/day), is efficacious for improvement of motor symptoms in advanced PD patients receiving levodopa treatment [5–7]. Now, zonisamide is approved as an adjunctive treatment in patients with advanced PD who show insufficient response to levodopa.
treatment. Moreover, recently, it has been reported that zonisamide monotherapy is effective for treatment in de novo patients with early PD [8].

The precise mechanisms of zonisamide for PD are not clearly understood yet. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide [9, 10]; however, it is still unclear whether the effect of zonisamide is mainly due to dopaminergic modification in the striatum, or if zonisamide works through non-dopaminergic pathways.

A 6-hydroxydopamine- (6-OHDA-) lesioned hemi-dopamine denervated rat is a well-established animal model of PD. This rat responds very sharply to dopaminergic stimulation in the lesioned striatum and presents marked abnormal involuntary movements (AIMs) in its body contralateral to the lesion [11, 12]. Behavioral analysis of this animal model may shed light on the mechanisms of zonisamide. We conducted the present study to determine the mechanism that is mainly responsible for zonisamide’s effects in PD. The aim of the present study is to examine the effects of zonisamide on motor symptoms in a hemiparkinsonian rat when administered singly, coadministered with levodopa, a dopamine precursor, or apomorphine, a D1 and D2 dopamine receptor agonist.

2. Materials and Methods

2.1. Animals. We used 44 male Wistar rats (CLEA Japan Inc., Tokyo, Japan) in this study. The experimental procedures complied with the "Principles of Laboratory Animal Care" (NIH Publication Vol 25, No. 28 revised 1996; http://grants.nih.gov/grants/guide/notice-files/not96-208.html) and the guidelines for animal research issued by the Physiological Society of Japan and by Hiroasaki University School of Medicine. All efforts were made to minimize the number of animals used and their suffering.

2.2. Surgery to Create Hemiparkinsonian Rats. At 10 weeks of age, all the rats underwent stereotactic infusion of 6-OHDA (Sigma, San Diego, CA, USA) into the medial forebrain bundle on the right side. The rats were pretreated with desipramine (25 mg/kg, intraperitoneally) (Sigma) 30 min before the injection of 6-OHDA to prevent the denervation of noradrenergic neurons. A stainless steel needle (0.4 mm diameter) was inserted through a small burr hole on the right side of the skull, and the needle tip was placed in the right medial forebrain bundle (4.5 mm posterior to the bregma, 1.2 mm lateral to the sagittal suture, and 8.5 mm ventral to the periosteum surface) according to the atlas of Paxinos and Watson [13]. We injected 6-OHDA (8 µg/4 µL in saline with 0.01% ascorbic acid) over 4 min. After injection, the needle was left in place for 2 min to prevent backflow leakage from the injection site. To evaluate the extent of dopaminergic denervation, 2 weeks after the 6-OHDA injection, the rats were challenged with an apomorphine (Sigma) injection (in saline with 0.1% ascorbic acid, 0.05 mg/kg, subcutaneously). Rats that made more than 20 contralateral (to the left) turns during a 5 min period between 15 and 20 min after the apomorphine injection, indicating a lack of dopaminergic function in the striatum, were considered to be a model of PD and were included in the present study. We have previously shown that rats meeting this criterion have lost more than 99% of the dopamine in their striatum [14].

2.3. Drug Treatment. Seven weeks after the surgery (5 weeks after the apomorphine test), the rats were randomly allocated to one of five groups: 14 rats received levodopa methyl ester only (6 mg/kg, intraperitoneal injection) (Sigma), 12 rats received levodopa (6 mg/kg) plus zonisamide (50 mg/kg, intraperitoneal injection), six rats received apomorphine only (0.05 mg/kg, subcutaneous injection), six rats received apomorphine (0.05 mg/kg) plus zonisamide (50 mg/kg), and six rats received zonisamide only (50 mg/kg). Rats in the levodopa only group and the levodopa plus zonisamide group also received benzeraside (10 mg/kg, intraperitoneal injection) (Sigma) at the same time as the levodopa injection to prevent peripheral decarboxylation of levodopa. Zonisamide was provided by Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan. All drugs were administered once daily for 15 days.

2.4. Behavioral Analyses. An AIM score [11] was measured every 20 min during the 3 h period following the injection of levodopa (nine times) on treatment Days 1, 8, and 15. Scores were based on the duration and persistence of involuntary purposeless behavior during the 1 min observation period. AIMs were classified into four subtypes: locomotive dystonia, axial dystonia, limb dyskinesia, and orolingual dyskinesia (see video links published in [15]). For each of the four subtypes, each rat was scored on a scale from 0–4: 1 = occasional; 2 = frequent; 3 = continuous but interrupted by sensory distraction; and 4 = continuous, severe, and not interrupted by sensory distraction [11]. The observer who scored the AIM (MT) was blind to the treatment condition. It has been shown that, among the four subtypes of AIMs in 6-OHDA-lesioned levodopa-treated rats, three subtypes, axial dystonia, limb dyskinesia, and orolingual dyskinesia, are equivalent to levodopa-induced dyskinesia (LID) in patients with PD [12, 16, 17]. In contrast, locomotive dyskinesia has been reported to be induced by not only levodopa but also by long-acting dopamine agonists [17, 18], and thus does not provide any specific measure of levodopa-induced motor complications [12, 16, 17]. Thus, the total score of axial dystonia, limb dyskinesia, and orolingual dyskinesia (ALO AIM score) has been used as an index of severity of LID.

2.5. Western Blot Analysis. Rats were sacrificed by decapitation after AIM scoring on treatment Day 15. Brains were dissected out and frozen rapidly at −70°C. For the present study, the dopamine-denervated striatum of rats treated with levodopa only (n = 6) and rats treated with levodopa plus zonisamide (n = 4) were subjected to immunoblotting. Western blot analysis was performed as described previously [19]. Rabbit polyclonal anti-dopa decarboxylase (DDC) (PAB9598; Abnova, Taipei, Taiwan;
We performed western blot (Figure 4). Zonisamide treatment had no impact on apomorphine-induced AIMs. Zonisamide monotherapy induced no AIMs. Thus, zonisamide appears to elicit beneficial effects for PD through modification of levodopa-dopamine metabolism in the striatum.

Our result is in agreement with a previous report that zonisamide enhances levodopa-induced rotational behavior in 6-OHDA-lesioned parkinsonian rats [20]. However, Oki et al. have recently reported that zonisamide decreases levodopa-induced dyskinesia-like behavior in the same rat model of PD, although the effect was minimal [21]. In their experiment, the levodopa dose was 12 mg/kg twice a day, which is four times the dose per day that was used in our experiment. Inconsistency between the studies may be due to the drug dose, and further examinations using various drug doses are required to resolve this issue.

When used at the therapeutic dose for epilepsy, zonisamide has been reported to increase dopamine concentration in normal rat striatum [22, 23]. Previously proposed mechanisms of the zonisamide-induced increase in dopamine concentration are activation of tyrosine hydroxylase [9] and inhibition of monoamine oxidase (MAO)-B [24, 25]. However, tyrosine hydroxylase is not involved in levodopa metabolism, and MAO-B has a minor role in dopamine oxidation in the rat brain [26, 27]. Thus, neither mechanism can fully explain the enhanced levodopa effect in the present study. In clinical situations, MAO-B inhibition apparently has beneficial effects on PD symptoms [28]. Clinical effects of zonisamide may be partly due to MAO-B inhibition; however, the results of the present study using a rodent model may not be explained by reduced activity of MAO-B. A recent study using cultured cells from mice has shown that zonisamide can inhibit both MAO-A and MAO-B [29]. MAO-A inhibition may explain the present result, although further studies using parkinsonian model would be required to support this idea.

Zonisamide increases the extracellular dopamine concentration after levodopa administration in the dopamine-denervated striatum in a rat model of Parkinson’s disease [30]. It has also been shown that 3,4-dihydroxyphenylacetic acid, a metabolite of dopamine, increases with co-administration of zonisamide and levodopa when compared with levodopa alone, although this effect was not seen in all of the parkinsonian rats [20]. Our western blot analyses showed no change in striatal expression of DDC or VMAT-2, suggesting that dopamine release may not be responsible for the dopaminergic effect of zonisamide. Inhibition of reuptake of levodopa-derived dopamine is another possible mechanism of the dopaminergic effect of zonisamide. In the dopamine-denervated striatum, extracellular dopamine is uptaken by the norepinephrine transporter, serotonin transporter, organic cation transporter-3, and plasma membrane monoamine transporter [31]. These transporters could be targets for the drug to elicit beneficial effects for PD through modification of levodopa-dopamine metabolism in the striatum.
Figure 1: The 3 h totals of abnormal involuntary movement (AIM) scores on treatment Days 1, 8, and 15 in the levodopa only group and levodopa plus zonisamide group. AIM scores are shown for four subtypes: locomotive dyskinesia (a), axial dystonia (b), limb dyskinesia (c), and orolingual dyskinesia (d) and for the total score of axial dystonia, limb dyskinesia, and orolingual dyskinesia (ALO AIM) (e). Diamonds indicate the scores of the levodopa only group, and squares indicate the scores of the levodopa plus zonisamide group. Data are expressed as mean ± standard deviation. *p < 0.05; **p < 0.01 compared with the levodopa only group.

Figure 2: The 3 h totals of abnormal involuntary movement (AIM) scores on treatment Days 1, 8, and 15 in the apomorphine only group, apomorphine plus zonisamide group, and zonisamide only group. AIM scores are shown for four subtypes: locomotive dyskinesia (a), axial dystonia (b), limb dyskinesia (c), and orolingual dyskinesia (d), and for the total score of axial dystonia, limb dyskinesia, and orolingual dyskinesia (ALO AIM) (e). There were no significant differences between the apomorphine only group and apomorphine plus zonisamide group. Diamonds indicate the scores of the apomorphine only group, squares indicate the scores of the apomorphine plus zonisamide group, and triangles indicate the scores of the zonisamide only group. Data are expressed as mean ± standard deviation. NS, not significant.
Figure 3: Abnormal involuntary movement (AIM) scores at each time point after drug injection on treatment Day 15 in the levodopa only group and the levodopa plus zonisamide group. AIM scores are shown for four subtypes: locomotive dyskinesia (a), axial dystonia (b), limb dyskinesia (c), and orolingual dyskinesia (d), and for the total score of axial dystonia, limb dyskinesia, and orolingual dyskinesia (ALO AIM) (e). Diamonds indicate the scores of the levodopa only group and squares indicate the scores of the levodopa plus zonisamide group. Data are expressed as mean ± standard deviation. *p < 0.05; **p < 0.01 compared with the levodopa only group.

Figure 4: Abnormal involuntary movement (AIM) scores at each time point after drug injection on treatment Day 15 in the apomorphine only group and the apomorphine plus zonisamide group. AIM scores are shown for four subtypes: locomotive dyskinesia (a), axial dystonia (b), limb dyskinesia (c), and orolingual dyskinesia (d), and for the total score of axial dystonia, limb dyskinesia, and orolingual dyskinesia (ALO AIM) (e). There were no significant differences between the groups. Diamonds indicate the scores of the apomorphine only group and squares indicate the scores of the apomorphine plus zonisamide group. Data are expressed as mean ± standard deviation. NS, not significant.
of zonisamide in its beneficial effects for PD. Whether functions of these transporters are modified by zonisamide should be examined in the future studies.

There are some limitations of the present study. First, the behavioral assessment focused only on dyskinesia-like movements. Using the AIM scoring method, it is difficult to distinguish improvement of akinesia from induction of dyskinesia in a rodent model of PD. Evaluation of the effect on motor symptoms of PD using other behavioral testing, such as the cylinder test, forepaw steps test, and rotarod test, is warranted to gain a more comprehensive understanding of the drug effects on behavior. Moreover, future studies using a primate model are required to confirm the effect of zonisamide. Second, striatal dopamine levels after drug treatment were not measured in the present study. To support our idea that zonisamide alters the striatal dopamine levels after levodopa administration, further studies are required with direct measurement of dopamine levels in the striatum with our animal PD model and experimental settings.

In conclusion, zonisamide appears to elicit its anti-parkinsonian effects by modulating levodopa-dopamine metabolism in the striatum.

Data Availability

All the raw data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

Dr. Shinya Ueno has received research grants from Shionogi & Co., Ltd, Eli Lilly Japan K.K., and Sumitomo Dainippon Pharma Co., Ltd. The other authors declare that they have no conflicts of interest.

Authors’ Contributions

Haruo Nishijima, Yasuo Mik, Shinya Ueno, and Masahiko Tomiyama were responsible for conception and design of the study, data interpretation, drafting the article or revising it critically for important intellectual content, and final approval of the version to be submitted; Haruo Nishijima, Yasuo Mik, and Masahiko Tomiyama were involved data acquisition and analysis.

Acknowledgments

This study was performed as a collaborative research with Sumitomo Dainippon Pharma Co., Ltd. We especially thank Ms. Saeko Osanai for her kind support in our laboratory. We thank Lesley McCollum, PhD, from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript. This study was supported by a research grant from Sumitomo Dainippon Pharma Co., Ltd. to Shinya Ueno.

References

[1] J. Jankovic, “Parkinson’s disease: clinical features and diagnosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368–376, 2008.
[2] N. B. Mercuri and G. Bernardi, “The ‘magic’ of L-dopa: why is it the gold standard Parkinson’s disease therapy?,” Trends in Pharmacological Sciences, vol. 26, no. 7, pp. 341–344, 2005.
[3] W. Oertel and J. B. Schulz, “Current and experimental treatments of Parkinson disease: a guide for neuroscientists,” Journal of Neurochemistry, vol. 139, no. 1, pp. 325–337, 2016.
[4] M. Murata, E. Horiuchi, and I. Kanazawa, “Zonisamide has beneficial effects on Parkinson’s disease patients,” Neuroscience Research, vol. 41, no. 4, pp. 397–399, 2001.
[5] M. Murata, K. Hasegawa, I. Kanazawa, and P. D. S. G. Japan Zonisamide on, “Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study,” Neurology, vol. 68, no. 1, pp. 45–50, 2007.
[6] M. Murata, K. Hasegawa, I. Kanazawa et al., “Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study,” Movement Disorders, vol. 30, no. 10, pp. 1343–1350, 2015.
[7] M. Murata, K. Hasegawa, I. Kanazawa et al., “Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease,” Neurology and Clinical Neuroscience, vol. 4, no. 1, pp. 10–15, 2016.
Parkinson’s Disease

[8] K. Ikeda, S. Hanashiro, M. Sawada, and Y. Iwasaki, “Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson’s disease,” Neurology and Clinical Neuroscience, vol. 3, no. 5, pp. 163–166, 2015.

[9] M. Murata, “Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease,” Current Pharmaceutical Design, vol. 10, no. 6, pp. 687–693, 2004.

[10] N. D. Grover, R. P. Limaye, D. V. Gokhale, T. R. Patil, and Zonisamide, “A review of the clinical and experimental evidence for its use in Parkinson’s disease,” Indian Journal of Pharmacology, vol. 45, no. 6, pp. 547–555, 2013.

[11] M. A. Cenci and M. Lundblad, “Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice,” Current Protocols in Neuroscience, vol. 9, p. 25, 2007.

[12] M. A. Cenci and A. R. Crossman, “Animal models of L-dopa-induced dyskinesia in Parkinson’s disease,” Movement Disorders, vol. 33, no. 6, pp. 889–899, 2018.

[13] G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press/Elsevier, Amsterdam, Netherlands, 6th edition, 2007.

[14] H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga, “Role of serotonergic neurons in L-DOPA-derivat ed extracellular dopamine in the striatum of 6-OHDA-lesioned rats,” NeuroReport, vol. 10, no. 3, pp. 631–634, 1999.

[15] H. Nishijima, T. Ueno, S. Ueno, and M. Tomiyama, “Duloxetine increases the effects of levodopa in a rat model of Parkinson’s disease,” Neurology and Clinical Neuroscience, vol. 4, no. 4, pp. 129–133, 2016.

[16] B. Henry, A. R. Crossman, and J. M. Brotchie, “Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease,” Experimental Neurology, vol. 191, no. 2, pp. 334–342, 1998.

[17] M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M. A. Cenci, “Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease,” European Journal of Neuroscience, vol. 15, no. 1, pp. 120–132, 2002.

[18] P. Ravenscroft, S. Chalon, J. M. Brotchie, and A. R. Crossman, “Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson’s disease: implications for dyskinesia,” Experimental Neurology, vol. 185, no. 1, pp. 36–46, 2004.

[19] Y. Miki, K. Tanji, F. Mori et al., “AMBRA1, a novel alpha-synuclein-binding protein, is implicated in the pathogenesis of multiple system atrophy,” Brain Pathology, vol. 28, no. 1, pp. 28–42, 2018.

[20] M. R. Gluck, L. A. Santana, H. Granson, and M. D. Yahr, “Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity,” Journal of Neural Transmission, vol. 111, no. 6, pp. 713–724, 2004.

[21] M. Oki, S. Kaneko, S. Morise et al., “Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats,” Neuroscience Research, vol. 122, pp. 45–50, 2017.

[22] M. Okada, S. Kaneko, T. Hirano et al., “Effects of zonisamide on dopaminergic system,” Epilepsy Research, vol. 22, no. 3, pp. 193–205, 1995.

[23] Y. Kawata, M. Okada, T. Murakami et al., “Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus,” Epilepsy Research, vol. 35, no. 3, pp. 173–182, 1999.